目的 系统评价羟考酮联合加巴喷丁应用中重度癌性疼痛的有效性和安全性。方法 检索PubMed、Medline、中国期刊全文数据库（CNKI）、维普中文科技期刊全文数据库（VIP）、中国生物医学全文数据库（CBM）和万方数据库中关于羟考酮联合加巴喷丁治疗癌性疼痛的随机对照研究，检索时限为2000年1月至2017年8月。由2名研究者独立提取数据、评价质量，并交叉核对。采用RevMan 5.2软件进行Meta-分析。结果 共纳入10项研究，687例患者。Meta-分析结果显示：羟考酮联合加巴喷丁较羟考酮单用能显著提高疼痛缓解率[OR=3.85，95%CI（2.25~6.60），P<0.000 01]和降低疼痛评分[MD=-0.83，95%CI（-0.95~-0.70），P<0.000 01]；能显著减少羟考酮的剂量[MD=-17.10，95%CI（-20.16~-14.04），P<0.000 01]；能显著减少便秘[OR=0.58，95%CI（0.42，0.82），P=0.002]和恶心呕吐[OR=0.55，95%CI（0.37，0.82），P=0.003]的发生率；能显著提高细胞免疫（CD4、CD8、CD4/CD8）和体液免疫（IgA、IgG、IgM）水平，差异均有统计学意义（P<0.01）。结论 羟考酮联合加巴喷丁能显著提高疼痛缓解率、降低疼痛评分，减少羟考酮平均日剂量，增强免疫功能，减少便秘和恶心呕吐等不良反应发生率，但两组头痛头晕、嗜睡和尿潴留的发生率无统计学差异。

Objective To systematically review oxycodone oral preparation combined with gabapentin for treating moderate and severe cancer pain.Methods Databases including PubMed, Medline, CNKI, VIP, CBM, and WanFang Data were searched to collect randomized controlled trials (RCTs) about oxycodone oral preparation combined with gabapentin for moderate and severe cancer pain from January 2000 to August 2017. Two reviewers independently screened literature, extracted data, and assessed the bias risk of included studies. Then meta-analysis was conducted by RevMan 5.2 software.Results Total 687 patients of 10 RCTs were included. Meta-analysis showed that, comparison on oxycodone alone, oxycodone combined with gabapentin could significantly improve the rate of pain relief[OR=3.85, 95%CI(2.25-6.60), P < 0.000 01] and lower pain score[MD=-0.83, 95%CI(-0.95--0.70), P < 0.000 01]; Significant reduction the daily dose of oxycodone[MD=-17.10, 95%CI(-20.16--14.04), P < 0.000 01]; Significantly reduced the incidence of constipation[OR=0.58, 95%CI(0.42, 0.82), P=0.002], nausea and vomiting[OR=0.55, 95%CI(0.37, 0.82), P=0.003]; Meanwhile it could improve the level of cellular immunity (CD4, CD8, and CD4/CD8) and humoral immunity (IgA, IgG, and IgM), the difference was statistically significant (P < 0.01).Conclusion Oxycodone combined with gabapentin can significantly improve the pain relief rate, reduce pain score and average daily dose of oxycodone, enhance immune function, reduce the rate of constipation mnausea and vomiting, but will not significantly affect incidence in headache dizziness, lethargy, and urinary retention.